Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseases

a prognostic marker and atherosclerosis technology, applied in the field of soluble cd40l, can solve the problem of predicting an increased risk of myocardial infarction, and achieve the effects of reducing the risk of the subject, preventing cardiovascular disorders, and limiting further injury

Inactive Publication Date: 2008-03-06
THE BRIGHAM & WOMEN S HOSPITAL INC
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes new tests that can predict who will develop cardiovascular diseases like heart attacks and strokes in the future. These tests measure a protein called sCD40L, which is elevated in people who have already had these diseases. The tests can also help determine which treatments will benefit or harm individuals based on their sCD40L levels. This information can be used to develop personalized treatment plans for cardiovascular disease.

Problems solved by technology

For example, elevated levels of sCD40L in apparently healthy, nonsmokers are predictive of an increased risk of myocardial infarction.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseases
  • Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

REFERENCES INCORPORATED IN EXAMPLE 1

[0116] 1. Alderson M R, Armitage R J, Tough T W, et al. J Exp Med. 1993; 178:669-74.

[0117] 2. Reul R M, Fang J C, Denton M D, et al. Transplantation. 1997; 64:1765-74.

[0118] 3. Mach F, Schönbeck U, Sukhova G K, et al. Proc Natl Acad Sci USA. 1997; 94:1931-6.

[0119] 4. Henn V, Slupsky J R, Grafe M, et al. Nature. 1998;391:591-4.

[0120] 5. Schönbeck U, Libby P. Cell Mol Life Sci. 2001; 58:4-43.

[0121] 6. Mach F, Schonbeck U, Sukhova G K, et al. Nature. 1998; 394:200-3.

[0122] 7. Schönbeck U, Sukhova G K, Shimizu K, et al. Proc Natl Acad Sci U S A. 2000; 97:7458-63.

[0123] 8. Lutgens E, Cleutjens K B, Heeneman S, et al. Proc Natl Acad Sci U S A. 2000; 97:7464-9.

[0124] 9. Graf D, Muller S, Korthauer U, et al. Eur J Immunol. 1995; 25:1749-54.

[0125] 10. Aukrust P, Muller F, Ueland T, et al. Circulation. 1999; 100:614-20.

[0126] 11. Buring J E, Hennekens C H. J. Myocard. Ischemia. 1992; 4:19-27.

[0127] 12. Ridker P M, Hennekens C H, Buring J E, et al...

example 2

REFERENCES INCORPORATED IN EXAMPLE 2

[0151] 1. Libby P, Hansson G K. Lab. Invest. 1991; 64:5-15.

[0152] 2. Ross R. N Engl J Med 1999; 340:115-126.

[0153] 3. Reul R M, Fang J C, Denton M D, et al. Transplantation. 1997; 64:1765-1774.

[0154] 4. Mach F, Schönbeck U, Sukhova G K, et al. Proc Natl Acad Sci U S A. 1997; 94:1931-1936.

[0155] 5. Gaweco A S, Wiesner R H, Yong S, et al. Liver Transpl. Surg. 1999; 5:1-7.

[0156] 6. Afford S C, Randhawa S, Eliopoulos A G, et al. J Exp Med. 1999; 189:441-446.

[0157] 7. Malik N, Greenfield B W, Wahl A F, et al. J Immunol. 1996; 156:3952-3960.

[0158] 8. Zhou L, Stordeur P, de Lavareille A, et al. Thromb. Haemost. 1998; 79:1025-1028.

[0159] 9. Miller D L, Yaron R, Yellin M J. J Leukoc Biol. 1998; 63:373-379.

[0160] 10. Slupsky J R, Kalbas M, Willuweit A, et al. Thromb Haemost. 1998; 80:1008-1014.

[0161] 11. Schönbeck U, Libby P. Cell Mol Life Sci. 2001; 58:4-43.

[0162] 12. Schönbeck U, Libby P. Circ Res. 2001; 89:1092-1103.

[0163] 13. Mach F, Schönbe...

example 3

REFERENCES INCORPORATED IN EXAMPLE 3

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
solubleaaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.

Description

RELATED APPLICATIONS [0001] This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Application Ser. No. 60 / 338,841, filed Nov. 5, 2001, and entitled: SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES incorporated herein in its entirety by reference.GOVERNMENT SUPPORT [0002] The work leading to the present invention was funded in part by grant numbers HL-34636, HL-56985, HL-58755, HL-63293 from the National Heart, Lung and Blood Institute. Accordingly, the United States Government may have certain rights to this invention.FIELD OF THE INVENTION [0003] This invention describes the new use of a diagnostic test to determine the risk of cardiovascular disorders, such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention describes the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/19A61K31/40A61K31/435A61K31/44A61P9/10G01N33/00G01N33/53A61K31/22A61K38/17A61K45/00A61P3/06G01N33/68
CPCA61K38/1709G01N33/6893G01N2800/324G01N2800/323G01N2800/32A61P3/06A61P9/10G01N33/53G01N33/567
Inventor SCHONBECK, UWERIDKER, PAULLIBBY, PETER
Owner THE BRIGHAM & WOMEN S HOSPITAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com